DRG Market Assessment reports

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to…

MARKET OUTLOOK Renal inflammation associated with systemic lupus erythematosus (SLE), also known as lupus nephritis (LN), is among the most serious manifestations of the disease. Presently, no…

Although angiogenesis inhibitors are a mainstay in the treatment of renal cell carcinoma, Bristol-Myers Squibb/Ono Pharmaceutical’s PD-1 inhibitor, Opdivo, has captured significant market share…

The treatment armamentarium for renal cell carcinoma mainly comprises small-molecule antiangiogenic inhibitors and immune checkpoint inhibitors. Bristol-Myers Squibb/Ono Pharmaceutical’s PD-1…

MARKET OUTLOOK Two of the largest U.S. pharmacy benefit managers, Express Scripts and CVS Health, set in motion a new approach to drug reimbursement by introducing indication-specific pricing (…

MARKET OUTLOOK Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide spectrum of clinical symptoms ranging from…

Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different systems and organs of the body and manifest with a wide spectrum of clinical symptoms. Lupus nephritis (LN) is…

Antineoplastic treatment in stage IV renal cell carcinoma is with targeted agents. The market entry of an immune checkpoint inhibitor has revolutionized the treatment algorithm for previously…

Market Outlook: Angiogenesis inhibitors continue to be the mainstay of first-line and second-line advanced or metastatic renal cell carcinoma. While PD-1 inhibitor, Opdivo entry in the second-…

The renal cell carcinoma drug market in Europe is increasingly competitive. Angiogenesis inhibitors (such as Pfizer’s Sutent and Novartis’s Votrient) and mTOR inhibitors (Pfizer’s Torisel and…

Immune checkpoint inhibitors (ICIs), including Bristol-Myers Squibb’s Opdivo and Yervoy and Merck & Co.’s Keytruda, are revolutionizing the therapeutic strategies for several cancers, notably…